ABK Biomedical Inc. news

ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration with Auckland Hospital Research Unit, New Zealand.

The prospective, single-center, open

ABK Biomedical, Inc., an innovative, clinical stage medical device company dedicated to the research, development and commercialization of advanced embolic therapies, announced the approval and initiation of a First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device, in collaboration with Auckland Hospital Research Unit, New Zealand.

The prospective, single-center, open-label study will evaluate the safety and effectiveness of Eye90 microspheres&trade

ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry for cutting-edge treatment of liver tumours – has partnered with the Canadian Nuclear Isotope Council.

The CNIC is an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups to help deliver innovative cancer treatments to patients. ABK Biomedical is the lat

ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems.

ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres™, which are designed for transarterial radiation therapy for liver tumors, and its Easi-Vue™ microspheres for